Category: Research
Review: cutaneous melanoma in the context of aging
Ageing is sustained by a complex network of cellular and molecular mechanisms. The main mechanisms are cellular senescence, telomere attrition, gene expression changes, metabolic dysregulations, oxida…
Read more about 'Review: cutaneous melanoma in the context of aging'...
Semaphorin 5 A is a novel player of melanoma aggressiveness and progression
Introduction: Metastatic potential and rising incidence make cutaneous melanoma a major health concern worldwide. While current therapies have proven effective, they are limited by side effects arisin…
Read more about 'Semaphorin 5 A is a novel player of melanoma aggressiveness and progression'...
Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma
Background: Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), have transformed the management of s…
Tattoos may be a risk factor for cutaneous melanoma
The incidence of cutaneous melanoma (CM) has risen sharply over the past 30 years, coinciding with the rapidly growing tattoo trend. In Sweden, 20% of the population is tattooed. Repeated reports of t…
Read more about 'Tattoos may be a risk factor for cutaneous melanoma'...
RAS(ON) multi-selective inhibition offering the first targeted approach for patients with NRAS-mutant melanoma
Targeted therapies for NRAS-mutant melanoma remain an unmet clinical need. Here, we demonstrate that RMC-7977, a preclinical RAS(ON) multi-selective inhibitor representative of the investigational age…
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors
Patients who initially respond to immune checkpoint inhibitors (ICIs) often relapse. Here, we studied how disease-progressive (DP) clinical melanomas evolve genomically to acquire ICI resistance. Comp…
Review of keratinocyte carcinoma
Importance: Keratinocyte carcinomas are skin cancers that arise from keratinocytes and are composed of basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Keratinocyte carcino…
Stage II melanoma: Is there a “simple trick” to significantly improve event-free survival?
On occasion, a therapeutic development makes a meaningful difference in patient outcomes without involvement of a new, expensive drug. An outstanding example of this in melanoma is the adoption of neo…
9-year final data support sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab for resected stage III or IV melanoma
Background: In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab.…
Adjuvant nivolumab plus relatlimab does not improve recurrence-free survival compared with nivolumab alone after complete resection of stage III/IV melanoma
Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the…